GlassScriptPhysician profile
Melissa Baker
NPI 1598451197
$6,910.58
in general payments reported to CMS, 2019-2025
23 companies · $4,636 in 2025
The $4,636 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $38.64 · 2024: $2,236 · 2025: $4,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,569 · Consulting Fee: $1,195 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,568.79 |
| Consulting Fee | $1,195.00 |
| Education | $146.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $1,569.21 | 2024-2025 | Dupixent |
| Abbvie INC. | $1,312.50 | 2024-2025 | |
| Janssen Biotech, INC. | $630.91 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $588.76 | 2024-2025 | Xifaxan, Trulance |
| Pfizer INC. | $413.36 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $387.42 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $264.22 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $225.23 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $193.12 | 2025 | Ibsrela |
| Boston Scientific Corporation | $192.17 | 2023-2025 | Varithena Administration Pack |
| Genzyme Corporation | $154.31 | 2025 | |
| Gilead Sciences, INC. | $152.91 | 2024 | Livdelzi |
| Madrigal Pharmaceuticals | $151.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $124.74 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $124.05 | 2024-2025 | Iqirvo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $106.93 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $95.35 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $81.73 | 2024-2025 | Vegzelma |
| Organon LLC | $42.68 | 2025 | Hadlima, Renflexis |
| Ironwood Pharmaceuticals, INC | $34.08 | 2024-2025 | |
| Evoke Pharma, INC. | $28.34 | 2025 | |
| Janssen Scientific Affairs, LLC | $20.40 | 2025 | Tremfya |
| Novo Nordisk INC | $17.13 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.